anti-TROP2/anti-CD3 bispecific monoclonal antibody(Roche)

N/A

Report date: 2026/04/17 20:02:02

Base Information

Drug Nameanti-TROP2/anti-CD3 bispecific monoclonal antibody(Roche)

Drug Alias NameTROP2/CD3 bispecific monoclonal antibody(Roche)

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionAnti-Trop-2Anti-CD3

TargetsTumor-associated calcium signal transducer 2T cell surface glycoprotein CD3

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySwitzerland

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesF. Hoffmann-La Roche Ag

China Registration ClassN/A

Develop Information

Active CompaniesF. Hoffmann-La Roche Ag

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A